Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference

Data to be featured in one poster and two oral presentations

WATERTOWN, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR^® platform to develop tolerogenic therapies for autoimmune diseases, today announced three upcoming presentations, including one joint presentation with our partner AskBio, at the 29^th Annual European Society of Gene and Cell Therapy (ESGCT) Conference, to be held virtually and in-person from October 11-14 in Edinburgh, United Kingdom. These presentations demonstrate the therapeutic utility of Selecta’s immune tolerance platform, ImmTOR^®, to enable safe repeated vector doses and mitigate unwanted immune responses to AAV capsids.

“We are thrilled to present data demonstrating the power of ImmTOR combined with T-reg specific IL-2 mutein (ImmTOR-IL™),” said Dr. Kei Kishimoto, Ph.D., Chief Scientific Officer of Selecta. “Our evolving precision immune tolerance platform is designed to enable AAV vector redosing by amplifying the magnitude and duration of effectively inhibiting the formation of anti-AAV antibodies, while simultaneously mitigating adverse responses associated with high AAV doses. We look forward to building on the encouraging data generated to date and remain on track to initiate our Phase 1 clinical trial for the treatment of methylmalonic acidemia in adolescents later this year. In parallel, we will continue our pioneering efforts to help gene therapy patients overcome immunogenicity.”

Details from ESGCT presentations are as follows:

Selecta Presentation Title: ImmTOR tolerogenic nanoparticles combined with Treg-selective IL-2 mutein induces massive expansion of antigen-specific regulatory T cells and synergistically inhibit formation of anti-AAV antibodies to high vector doses
Presentation Number: OR07
Presenter: Kei Kishimoto, Ph.D., Selecta Biosciences
Presentation Date and Time Slot: Tuesday, October 11 | 5:45 p.m. GMT

Selecta Presentation Title: A strategy to mitigate toxicities associated with AAV doses of 1E14 vg/kg or higher by enabling repeated vector administrations at 5E13 vg/kg
Presentation Number: P517
Presenter: Petr Ilyinskii, Ph.D., Selecta Biosciences
Presentation Date and Time Slot: Wednesday, October 12 | 7:30 p.m. GMT

Selecta & AskBio Presentation Title: Using a systems biology approach to unravel the Immunogenicity of AAV8 empty capsids in healthy volunteers
Presentation Number: OR06
Presenter: Greg Gojanovich, Ph.D., AskBio
Presentation Date and Time Slot: Tuesday, October 11 | 5:30 p.m. GMT

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR^® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

Selecta Forward-Looking Statements
Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (the “Company”), including without limitation, statements regarding the unique proprietary technology platform of the Company, and the unique proprietary platform of its partners, the potential of ImmTOR to enable re-dosing of AAV gene therapy and to mitigate immunogenicity, the potential of ImmTOR and the Company’s product pipeline to treat chronic refractory gout, MMA, IgAN, other autoimmune diseases, lysosomal storage disorders, or any other disease, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, the anticipated timing or the outcome of the FDA’s review of the Company’s regulatory filings, the Company’s and its partners’ ability to conduct its and their clinical trials and preclinical studies, the timing or making of any regulatory filings, the potential treatment applications of product candidates utilizing the ImmTOR platform in areas such as gene therapy, gout and autoimmune disease, the ability of the Company and its partners where applicable to develop gene therapy products using ImmTOR, the novelty of treatment paradigms that the Company is able to develop, whether the observations made in non-human study subjects will translate to studies performed with human beings, the potential of any therapies developed by the Company to fulfill unmet medical needs, the Company’s plan to apply its ImmTOR technology platform to a range of biologics for rare and orphan genetic diseases, the potential of the Company’s technology to enable repeat administration in gene therapy product candidates and products, the ability to re-dose patients and the potential of ImmTOR to allow for re-dosing, the potential to safely re-dose AAV, the ability to restore transgene expression, the potential of the ImmTOR technology platform generally and the Company’s ability to grow its strategic partnerships, enrollment in the Company’s clinical trials and the Company’s plans with respect to areas affected by geopolitical conflict and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including the uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company’s ImmTOR technology, potential delays in enrollment of patients, undesirable side effects of the Company’s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the Company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s recurring losses from operations and negative cash flows, substantial fluctuation in the price of its common stock, risks related to geopolitical conflicts and pandemics and other important factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K, as supplemented by subsequent Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release except as required by law.

For investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-813-767-7801
bleigh@lifescicomms.com